Laverock reports positive data from oncology programmes
Laverock Therapeutics has reported in vivo functional milestones across its T-cell and macrophage oncology programmes as it advances its lead programme towards clinic.
Data from ovarian cancer models, presented at the American Society of Cell and Gene Therapy (ASCGT) Annual Meeting in May, demonstrated the company’s technology can improve solid tumour control by targeting three distinct immunomodulatory pathways simultaneously.
Laverock says its platform technology enables programmable, tuneable and multiplex gene control for both endogenous targets and for transgenically expressed payloads. In its T-cell programme (LVK201), the platform is designed to improve CAR-T cell anti-tumour activity without compromising safety.
The findings will allow Laverock to develop its lead programme, establishing a foundation for future tailored therapies across a range of solid tumour types.
“These key data points from our oncology programmes highlight the capabilities and strength of our platform technology, and provide a clear route to lead programme selection and progression into non-clinical studies,” said David Venables, Laverock Therapeutics CEO.
“Solid tumours remain an area of huge unmet need for cancer patients, and we look forward to moving our differentiated therapies towards the clinic.”
